500mg tablets of Depakote extended-release It is used primarily to treat epilepsy and bipolar disorder. It is also used to prevent migraine headaches. Epilepsy<unk>  has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizures, absence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms. It has also been successfully given intravenously to treat status epilepticus. Mental illness Bipolar disorder<unk>  products are also used to treat manic or mixed episodes of bipolar disorder. Schizophrenia A 2016 systematic review compared the efficacy of<unk>  as an add-on for people with schizophrenia: There is limited evidence that adding<unk>  to antipsychotics may be effective for overall response and also for specific symptoms, especially in terms of excitement and aggression.<unk>  was associated with a number of adverse events among which sedation and dizziness appeared more frequently than in the control groups. Outcome Findings in words Findings in numbers Quality of evidence Global outcome Clinically significant response When added to antipsychotic drugs<unk>  probably increases the chance of improvement. Data are based on moderate quality evidence. RR 1.31 (1.16 to 1.47) Moderate Leaving the study early for any reason<unk>  in combination with antipsychotics may slightly reduce the chance of leaving the study early, but the difference between the two treatments is not clear. Data supporting this finding are based on moderate quality evidence. RR 0.76 (0.47 to 1.24) Moderate Use of additional medication for sedation The combination of<unk>  and antipsychotic drugs may increase the chance of being given additional sedating medication, but, at present it is not possible to be confident about the difference between the two treatments and data supporting this finding are very limited. RR 3.65 (0.11 to 122.31) Very low Mental state Average score (PANSS total, high = poor) On average, people receiving the<unk>  combination scored lower (better) than people treated with antipsychotics in combination with placebo or antipsychotic drugs alone. There was a clear difference between the groups, but the meaning of this in day-to-day care is unclear. MD 5.85 lower (7.8 lower to 3.91 lower) Moderate Adverse events Abnormal liver function (blood test changes)* Adding<unk>  to antipsychotic drug treatment does not clearly cause liver problems. Data supporting this finding are based on moderate quality evidence. RR 1.26 (0.72 to 2.22) Moderate Nausea Adding<unk>  to antipsychotic drugs probably causes little or no increase to the chance of feeling sick, but the difference between the two treatments is not clear. Data supporting this finding are based on moderate quality evidence. RR 1.22 (0.80 to 1.86) Moderate Missing outcomes and notes Quality of life outcomes were not reported in the included studies. *Increase in alanine transaminase/gamma-glutamyl transpeptidase Dopamine dysregulation syndrome Based upon five case reports,<unk> proic acid may have efficacy in controlling the symptoms of the dopamine dysregulation syndrome that arise from the treatment of Parkinson's disease with levodopa. Migraines<unk>  is also used to prevent migraine headaches. Because this medication can be potentially harmful to the fetus,<unk>  should be considered for those able to become pregnant only after the risks have been discussed. Other The medication has been tested in the treatment of AIDS and cancer, owing to its histone-deacetylase-inhibiting effects.
Valproate
Tiagabine
Retigabine
Lamotrigine
Felbamate
Topiramate
Mesuximide
Primidone